All In Biotech

Drug Trial Radar · NCT04201457

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

57

Actual

Start

Jan 17, 2020

Primary completion

Oct 1, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Pediatric Brain Tumor ConsortiumResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities
First posted
Dec 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.

Conditions

  • Low Grade Glioma (LGG) of Brain With BRAF Aberration
  • High Grade Glioma (HGG) of the Brain With BRAF Aberration
  • Low Grade Glioma of Brain With Neurofibromatosis Type 1

Interventions

  • DabrafenibDrug

    Dabrafenib capsule; Dabrafenib Dispersible Tablet

  • TrametinibDrug

    Tablet; Powder for Oral Solution

  • HydroxychloroquineDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)/ Recommended Phase 2 Dose (RP2D)Time frame: Approximately 28 days from start of therapy
  2. Maximum Plasma ConcentrationTime frame: 1-4 days
  3. Area under the curve (AUC)Time frame: 1-4 days
  4. Phase II: Sustained objective response rate.Time frame: Up to approximately 2 years from the start of therapy

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Lucile Packard Children's Hospital at Stanford University Medical Center

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

  • National Cancer Institute Pediatric Oncology Branch

    Bethesda, Maryland

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cincinnati Children Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • St. Jude Children Research Hospital

    Memphis, Tennessee

  • Texas Children's Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.